Pregled bibliografske jedinice broj: 1106484
Uncommon side effects of sunitinib therapy in a patient with metastatic renal cell cancer: case report
Uncommon side effects of sunitinib therapy in a patient with metastatic renal cell cancer: case report // Acta clinica Croatica, 57 (2018), 3; 577-580 doi:10.20471/acc.2018.57.03.22 (recenziran, članak, znanstveni)
CROSBI ID: 1106484 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Uncommon side effects of sunitinib therapy in a patient with metastatic renal cell cancer: case report
Autori
Šeparović, Robert ; Pavlović, Mirjana ; Silovski, Tajana ; Silovski, Hrvoje ; Tečić Vuger, Ana
Izvornik
Acta clinica Croatica (0353-9466) 57
(2018), 3;
577-580
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
sunitinib ; carcinoma ; renal cell ; drug-related side effects and adverse reactions ; pancreatitis ; acute kidney injury ; pancytopenia
Sažetak
Sunitinib is an orally administered multikinase inhibitor. This therapy can provoke uncommon side effects such as pancytopenia, tumor lysis syndrome, cardiac disorders, thromboembolic incidents, intestinal perforation, pancreatitis, acute renal failure, etc. We report a case of a 63-year-old female admitted to the hospital due to abdominal pain, nausea, vomiting and elevated blood pressure. One month earlier, sunitinib therapy for metastatic renal cell carcinoma was initiated. During the first cycle of therapy, after three weeks of sunitinib 50 mg daily, symptoms started and she stopped taking the drug. At admission, laboratory tests revealed elevated serum and urine amylase, C-reactive protein, urea and creatinine, and lowered platelet and leukocyte counts and hemoglobin value. Urine test showed proteinuria, erythrocyturia, leukocyturia and granulated cylinder. The patient was diagnosed with acute pancreatitis grade III, acute renal failure grade II, pancytopenia and urinary infection, and was hospitalized for five days. She was treated symptomatically and with antibiotic therapy because of persistently elevated C-reactive protein and pathologic urinary sediment, which led to subjective and clinical improvement. Acute pancreatitis, renal insufficiency and pancytopenia are rarely described side effects of sunitinib therapy, and clear connection between these conditions and drug activity is not yet determined. Medical specialists who prescribe and treat patients with sunitinib should be aware of the possible occurrence of these conditions and perform regular checkups of sunitinib treated patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za tumore,
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Klinički bolnički centar Zagreb
Profili:
Mirjana Pavlović
(autor)
Ana Tečić Vuger
(autor)
Hrvoje Silovski
(autor)
Tajana Silovski
(autor)
Robert Šeparović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE